Esophageal involvement of mantle cell lymphoma presenting with multiple lymphomatous polyposis: A single-center study

Table 1 Endoscopic findings of the gastrointestinal lesions

Case	Esophagus	Stomach	Duodenum	Terminal ileum-colon
1	MLP	Non-MLP (fold thickening + protruded)	MLP	MLP
2	MLP	MLP	MLP	MLP
3	MLP	Non-MLP (superficial)	MLP	Non-MLP (protruded)
4	MLP	Non-MLP (fold thickening + protruded)	MLP	MLP
5	MLP	MLP	(-)	Non-MLP (protruded)
6	MLP	(-)	MLP	MLP

Multiple lymphomatous polyposis was observed in all 6 patients with esophageal lesions, in 2 of the 5 patients with gastric lesions, in all 5 patients with duodenal lesions, and in 4 of the 6 patients with colonic lesions. MLP: Multiple lymphomatous polyposis.

Table 2 Clinical characteristics of 6 patients

Case	Age (year)	Sex	Lesion site (other than GI tract)	MIPI (score)	Treatment	Recurrence	Survival period
1	70	M	Cervical LN, inguinal LN, intra-abdominal LN, BM	Low (5.5)	THP•COP, Radiation ProMACE/CytaBOM, RTX (/+chemo)	(+)	13 years (death from MCL)
2	66	F	Submandibular LN, axillary LN, thyroid gland	Low (5.2)	R-CHOP, RTX + Cladribine, ProMACE/CytaBOM	(+)	1year 9 months (death from MCL)
3	75	M	Cervical LN, supraclavicular LN, axillary LN, hilar/mediastinal LN, intra-abdominal LN, inguinal LN, BM, PB, spleen, nasopharynx/palate	High (7.2)	THP•COP, R-BAC	Nearly CR	6 months (treatment-related deaths)
4	84	M	Intra-abdominal LN, BM, PB, spleen	Intermediate (6.1)	RTX (monotherapy)	Non-CR	1 year 10 months (death from MCL)
5	73	M	Submandibular-cervical LN, supraclavicular LN, axillary LN, intra-abdominal LN, inguinal LN, BM, PB, spleen, tonsil	High (6.7)	BR	Non-CR	1 year 11 months (death from MCL)
6	52	M	Submandibular-cervical LN, axillary LN, mediastinal LN, abdominal-pelvic LN, Inguinal LN, BM, PB, spleen, liver, tonsil	Intermediate (6.1)	CHOP, RTX + Ara-C/ETP R-BAC	(-)	3 year 3 months (alive with CR maintained)

GI: Gastrointestinal; LN: Lymph nodes; BM: Bone marrow; PB: Peripheral blood; MIPI: The Mantle Cell Lymphoma International Prognostic Index; THP-COP: Pirarubicin, cyclophosphamide, vincristine and prednisone; ProMACE/CytaBom: Cyclophosphamide, doxorubicin, etoposide on day 1, cytarabine, bleomycin, vincristine, methotrexate on day 8, and prednisone on days 1 through 14; RTX: Rituximab; R-THP-COP: Rituximab, pirarubicin, cyclophosphamide, vincristine and prednisone; R-BAC: Rituximab, bendamustine, cytarabine; BR: Rituximab, bendamustine; Ara-C: Cytarabine; ETP: Etoposide; CR: Complete remission; MCL: Mantle cell lymphoma.